Joseph Farmer has been appointed chief operating officer of Akrevia Therapeutics. Farmer comes to Cambridge, MA-based Akrevia from Tesaro, a cancer drug developer that was acquired by GlaxoSmithKline (NYSE: [[ticker:GSK]]) earlier this year. His experience also includes posts at Cubist Pharmaceuticals and AMAG Pharmaceuticals. Akrevia launched last year with a $30 million Series A round of funding to back its development of cancer immunotherapies intended to attack tumors in a more targeted way.